You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Mylan Institutional Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and what generic and branded alternatives to MYLAN INSTITUTIONAL drugs are available?

MYLAN INSTITUTIONAL has thirty-five approved drugs.

Summary for Mylan Institutional

US Patents:	0
Tradenames:	31
Ingredients:	30
NDAs:	35
Patent Litigation for Mylan Institutional:	See patent lawsuits for Mylan Institutional
PTAB Cases with Mylan Institutional as petitioner:	See PTAB cases with Mylan Institutional as petitioner

Drugs and US Patents for Mylan Institutional

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Institutional	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	040498-001	Jul 12, 2005	AP	RX	No	Yes		⤷ Subscribe				⤷ Subscribe
Mylan Institutional	OCTREOTIDE ACETATE (PRESERVATIVE FREE)	octreotide acetate	INJECTABLE;INJECTION	079198-001	Feb 10, 2011	AP	RX	No	No		⤷ Subscribe				⤷ Subscribe
Mylan Institutional	MESNA	mesna	INJECTABLE;INTRAVENOUS	076488-001	Mar 8, 2012		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Mylan Institutional	FOMEPIZOLE	fomepizole	INJECTABLE;INJECTION	078639-001	Mar 3, 2008	AP	RX	No	Yes		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Mylan Institutional

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Institutional	RIMSO-50	dimethyl sulfoxide	SOLUTION;INTRAVESICAL	017788-001	Approved Prior to Jan 1, 1982	3,549,770	⤷ Subscribe
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-002	Jul 12, 1996	5,466,700*PED	⤷ Subscribe
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-003	Jul 12, 1996	5,866,591*PED	⤷ Subscribe
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-001	Jul 12, 1996	5,019,583*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	for Injection	1 mg/vial, 2 mg/vial and 5 mg/vial	➤ Subscribe	2013-12-27
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.